ELAN Elanco Animal Health

Yousif Capital Management LLC significantly increased its stake in Elanco Animal Health Incorporated by 1,333.7% in Q3 2025, now holding 168,133 shares valued at $3.39 million. This comes as Elanco exceeded Q3 earnings expectations and provided strong FY2025 guidance. Insider buying and institutional ownership of nearly 97.48% also highlight confidence in the company.

Elanco Animal Health Incorporated (NYSE:ELAN) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $23.78. This comes alongside significant insider buying, with directors and the CEO acquiring shares totaling over $690,000 in recent transactions. The company also reported a strong Q3 beat with better-than-expected EPS and revenue, and has provided positive FY2025 guidance.

Elanco Animal Health Incorporated (NYSE:ELAN) has received a consensus "Moderate Buy" rating from thirteen analysts, with an average 12-month target price of $23.78. Recent insider transactions show CEO Jeffrey N. Simmons and director Lawrence Erik Kurzius purchasing shares, while institutional investors have significantly increased their stakes, now owning approximately 97.48% of the company. The company also surpassed quarterly earnings and revenue estimates and provided positive FY2025 guidance.

Hamilton Exhibits LLC created a "zen garden" exhibit for Elanco Animal Health Inc. to subtly promote a new pet dermatology medicine. The exhibit, named Zenrelia Garden, focused on creating a peaceful and relaxing environment to demonstrate the calming effects of the anti-itch medication, engaging multiple senses through activities like a sand pit and floral workshops. This design approach aimed to immerse attendees in a serene world away from the bustling trade show floor.

Douglas Lane & Associates LLC slightly reduced its stake in Elanco Animal Health Incorporated by 1.9% in Q3, now holding shares valued at over $69 million. Despite this, analysts largely maintain a "Moderate Buy" rating with an average target price of $23.78, and company insiders have been net buyers of the stock. Elanco Animal Health recently surpassed its quarterly earnings expectations and provided positive guidance for FY 2025.

Jim Cramer lauded Elanco Animal Health (NYSE: ELAN), stating they are "doing everything right" and expressing impression with the company's turnaround. Despite his positive remarks, he previously suggested Chewy as a better investment in the pet sector. Since Cramer's earlier comments, Elanco's stock has surged over 83%.